Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial
Related Posts
Mishra A, Solis NV, Dietz SM, Crouch AL, Filler SG, Anderson MZ. Strain background interacts with chromosome 7 aneuploidy to determine commensal and virulence phenotypes[...]
Landovitz RJ, Molina JM, Buchbinder SP; International Antiviral Society-USA (IAS-USA) Panel. Preexposure Prophylaxis for HIV: Updated Recommendations From the 2024 International Antiviral Society-USA Panel. JAMA.[...]
Corley MJ, Watanabe M, Pang APS, Dwaraka VB, Smith R, Samaneka W, Henn S, Munsiff S, Saumoy M, McCallum S, Fitch KV, Chu SM, Diggs[...]